

# PATENT ASSIGNMENT

Electronic Version v1.1

Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
Yan Wu	11/09/2009
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ImClone, LLC
<b>Street Address:</b>	180 Varick Street
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10014
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	12608034
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(317)276-3861
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Email:</b>	patents@lilly.com
<b>Correspondent Name:</b>	Eli Lilly and Company
<b>Address Line 1:</b>	P. O. Box 6288
<b>Address Line 2:</b>	Patent Division
<b>Address Line 4:</b>	Indianapolis, INDIANA 46206-6288
<b>ATTORNEY DOCKET NUMBER:</b>	X-18533
<b>NAME OF SUBMITTER:</b>	Linda M. Durbin
<b>Total Attachments: 2</b> source=X18533Assignment#page1.tif source=X18533Assignment#page2.tif	

CH \$40.00 12608034

501010702

**PATENT**  
**REEL: 023492 FRAME: 0919**

**ASSIGNMENT****WHEREAS,**

**Yan WU, 8 McPherson Drive, Flemington, NJ 08822, Citizen of United States**

(is, are) inventor(s) or co-inventor(s) (with the persons listed above) of an invention that is the subject of a patent application ("Application") which is entitled *ANTI-TGF-BETA RECEPTOR II ANTIBODIES*, containing 34 pages and 0 sheets of drawings, for filing:

- ☒ in the United States Patent and Trademark Office
- ☐ in the United Kingdom Patent Office
- ☐ in the European Patent Office
- ☐ in the Spanish Patent Office as a European Application
- ☐ as an international application under the Patent Cooperation Treaty ("PCT"), with United States Patent and Trademark Office acting as Receiving Office

And accorded the following serial number and filing date: 12/608034, 29-Oct-09.

If this application is filed after the signing of this assignment document, I hereby give permission to insert above the serial number and filing date for the application when it is known.

**WHEREAS IMCLONE, LLC**, a Delaware limited liability corporation having its principal place of business at 180 Varick Street, 6<sup>th</sup> Floor, New York, NY 10014, a wholly-owned subsidiary of Eli Lilly and Company, and Indiana corporation with a principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285 wishes to acquire the entire interest in all inventions disclosed in such Application:


**NOW, THEREFORE**, in consideration of my employment, any agreements related thereto, or other good and valuable consideration, the receipt of which is hereby acknowledged, I hereby assign to ImClone, LLC, its successors and assigns (collectively "ImClone") my entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in any country, inclusive of, but not limited to, continuations, continuations-in-part, divisions, substitutions, reexaminations, reissues, international applications filed under the PCT, United States provisional patent applications, subsequent United States provisional patent applications claiming some or all of this invention, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates; and any related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by ImClone for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by me had this Assignment and sale to ImClone not been made.

For myself and for my heirs, successors and legal representatives, I covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For myself and for my heirs, successors and legal representatives, I further covenant and agree with ImClone that upon request I and they will, without further consideration than that now paid, but at the expense of ImClone: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to ImClone any facts known to me or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for ImClone, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to ImClone or its nominees, in the United States and in all other countries where ImClone may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for ImClone and to vest and confirm in ImClone or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

I have executed this assignment on the date indicated below.

11-09-09  
Date

  
Yan WU